Phase II study of 90Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma

被引：21

作者：

Lossos, Izidore S. ^{[1
,4
]}

Fabregas, Jesus C. ^{[1
,4
]}

Koru-Sengul, Tulay ^{[2
,4
]}

Miao, Feng ^{[4
]}

Goodman, Deborah ^{[4
]}

Serafini, Aldo N. ^{[3
,4
]}

Hosein, Peter J. ^{[1
,4
]}

Stefanovic, Alexandra ^{[1
,4
]}

Rosenblatt, Joseph D. ^{[1
,4
]}

Hoffman, James E. ^{[1
,4
]}

机构：

[1] Univ Miami, Miller Sch Med, Dept Med, Div Hematol Oncol, Miami, FL 33136 USA

[2] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA

[3] Univ Miami, Miller Sch Med, Dept Radiol, Miami, FL 33136 USA

[4] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA

来源：

LEUKEMIA & LYMPHOMA | 2015年 / 56卷 / 06期

基金：

美国国家卫生研究院;

关键词：

Marginal zone lymphoma; radioininnunotherapy; Y-90 ibritumomab tiuxetan; B-CELL LYMPHOMA; LOW-GRADE; 1ST-LINE TREATMENT; CLINICAL ACTIVITY; TISSUE LYMPHOMA; RITUXIMAB; RADIOIMMUNOTHERAPY; CHLORAMBUCIL; CHEMOTHERAPY; EFFICACY;

D O I：

10.3109/10428194.2014.975801

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The best upfront therapy for patients with non-gastric extranodal marginal zone lymphomas (MZLs) is not defined. We assessed the safety and efficacy of radioimmunotherapy with with (90)yttrium (Y-90) ibritumomab tiuxetan as upfront therapy in MZL (NCT00453102). A total of 16 patients were enrolled, 81% with advanced-stage disease and 44% with bulky disease. The overall response rate (ORR) at 12 weeks post-therapy was 87.5% (90% confidence interval [Cl]: 65.6-97.7%), including a complete response in eight (50%), complete response unconfirmed in one (6%) and partial response in five (31%) patients. With a median follow-up of 65.6 months (range 4.0-96.5), the median progression-free survival (PFS) was 47.6 months (range 4.0-93.3) and median overall survival (OS) was not reached. The 5-year PFS was 40% (90% CI: 19.9-59.5%) and 5-year OS was 71.8% (90% Cl: 46.8-86.5%). Overall, Y-90 ibritumomab tiuxetan was well tolerated and led to long-term responses and PFS rates.

引用

页码：1750 / 1755

页数：6

共 34 条

[1] Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients [J].

Armitage, JO ;

Carbone, PP ;

Connors, JM ;

Levine, A ;

Bennett, JM ;

Kroll, S .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (05) :897-906

[2] Oral chlorambucil for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue of the orbit [J].

Ben Simon, Guy J. ;

Cheung, Ning ;

McKelvie, Penny ;

Fox, Richard ;

McNab, Alan A. .

OPHTHALMOLOGY, 2006, 113 (07) :1209-1213

[3] Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma [J].

Chen, LT ;

Lin, JT ;

Tai, JJ ;

Chen, GH ;

Yeh, HZ ;

Yang, SS ;

Wang, HP ;

Kuo, SH ;

Sheu, BS ;

Jan, CM ;

Wang, WM ;

Wang, TE ;

Wu, CW ;

Chen, CL ;

Su, IJ ;

Whang-Peng, J ;

Cheng, AL .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (18) :1345-1353

[4] Revised response criteria for malignant lymphoma [J].

Cheson, Bruce D. ;

Pfistner, Beate ;

Juweid, Malik E. ;

Gascoyne, Randy D. ;

Specht, Lena ;

Horning, Sandra J. ;

Coiffier, Bertrand ;

Fisher, Richard I. ;

Hagenbeek, Anton ;

Zucca, Emanuele ;

Rosen, Steven T. ;

Stroobants, Sigrid ;

Lister, T. Andrew ;

Hoppe, Richard T. ;

Dreyling, Martin ;

Tobinai, Kensei ;

Vose, Julie M. ;

Connors, Joseph M. ;

Federico, Massimo ;

Diehl, Volker .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :579-586

[5] Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type [J].

Conconi, A ;

Martinelli, G ;

Thiéblemont, C ;

Ferreri, AJM ;

Devizzi, L ;

Peccatori, F ;

Ponzoni, M ;

Pedrinis, E ;

Dell'Oro, S ;

Pruneri, G ;

Filipazzi, V ;

Dietrich, PY ;

Gianni, AM ;

Coiffier, B ;

Cavalli, F ;

Zucca, E .

BLOOD, 2003, 102 (08) :2741-2745

[6] Treatment-related Myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy [J].

Czuczman, Myron S. ;

Emmanouilides, Christos ;

Darif, Mohamed ;

Witzig, Thomas E. ;

Gordon, Leo I. ;

Revell, Stephen ;

Vo, Katie ;

Molina, Arturo .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (27) :4285-4292

[7] Results of a national consensus workshop:: therapeutic algorithm in patients with follicular lymphoma -: role of radioimmunotherapy [J].

Dreyling, M. ;

Truemper, L. ;

von Schilling, C. ;

Rummel, M. ;

Holtkamp, U. ;

Waldmann, A. ;

Wehmeyer, J. ;

Freund, M. .

ANNALS OF HEMATOLOGY, 2007, 86 (02) :81-87

[8] Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma [J].

Esmaeli, B. ;

McLaughlin, P. ;

Pro, B. ;

Samaniego, F. ;

Gayed, I. ;

Hagemeister, F. ;

Romaguera, J. ;

Cabanillas, F. ;

Neelapu, S. S. ;

Banay, R. ;

Fayad, L. ;

Saville, M. Wayne ;

Kwak, L. W. .

ANNALS OF ONCOLOGY, 2009, 20 (04) :709-714

[9]

Ferreri AJM, 2005, HAEMATOLOGICA, V90, P1578

[10] EFFICACY OF SINGLE-AGENT CHEMOTHERAPY IN LOW-GRADE B-CELL MUCOSA-ASSOCIATED LYMPHOID-TISSUE LYMPHOMA WITH PROMINENT GASTRIC EXPRESSION [J].

HAMMEL, P ;

HAIOUN, C ;

CHAUMETTE, MT ;

GAULARD, P ;

DIVINE, M ;

REYES, F ;

DELCHIER, JC .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (10) :2524-2529

← 1 2 3 4 →